Buprenorphine and Zuclopenthixol: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Zuclopenthixol
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both buprenorphine (a pain and opioid-dependence medicine) and zuclopenthixol (a medicine for certain mental health conditions) can each affect your heart's electrical rhythm in a way doctors call QT prolongation. When two medicines that do this are taken together, the effect can add up, which in rare cases can lead to an irregular heartbeat.
The good news is this is mostly a theoretical concern, meaning it's based on how the drugs work rather than a lot of real-world reports. Your care team can manage it safely by watching for it, especially if you have heart concerns or low potassium or magnesium. Please don't change anything on your own, just check in with your pharmacist or doctor.
Interaction: Additive risk of QT interval prolongation with concomitant buprenorphine and zuclopenthixol. Both agents are independently associated with QTc prolongation; neither is a prodrug, so this is a pharmacodynamic (additive), not pharmacokinetic, effect.
Direction/magnitude: Increased QTc, magnitude unquantified.
Evidence: Theoretical; combined risk not established.
Onset: Unspecified.
- Avoid concomitant use where feasible.
- Assess and correct modifiable risk factors: hypokalemia, hypomagnesemia, bradycardia, CHF, baseline/congenital QT prolongation, digitalis therapy, recent cardioversion.
- Consider baseline and follow-up ECG and electrolyte monitoring if co-prescribed.
What happens
An increased risk of QT interval prolongation
Interaction Deep Dive
Using buprenorphine at the same time as agents capable of extending the QT interval should be avoided 342. It remains unknown what risk arises from pairing buprenorphine with other QT-prolonging drugs. When prescribing buprenorphine to patients who carry risk factors, including hypokalemia, bradycardia, recent conversion from atrial fibrillation, congestive heart failure, digitalis therapy, baseline QT prolongation, subclinical long-QT syndrome, or severe hypomagnesemia, clinicians should weigh these considerations in their decisions 1.
Why it happens (mechanism)
Additive QT interval prolongation
How to manage this interaction
Both medicines can lengthen the QT interval, so the general guidance is to avoid using them together when possible. If your prescriber decides you do need both, this can still be managed safely.
- Keep taking both exactly as prescribed unless your care team tells you otherwise.
- Your team may check your heart rhythm (an ECG) and your potassium and magnesium levels, and correct them if needed.
- Tell your care team if you have heart failure, a slow or irregular heartbeat, or a history of QT problems.
- Report fainting, dizziness, or palpitations promptly.
Raise any concerns with your pharmacist or doctor before making changes.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Buprenorphine and Zuclopenthixol together?
Buprenorphine and zuclopenthixol can each prolong the QT interval, so the combination is best avoided when possible; if both are needed, your care team can manage it with monitoring and by keeping your electrolytes in check. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Zuclopenthixol interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Zuclopenthixol interaction managed?
Both medicines can lengthen the QT interval, so the general guidance is to avoid using them together when possible. If your prescriber decides you do need both, this can still be managed safely. Keep taking both exactly as prescribed unless your care team tells you otherwise. Your team may check your heart rhythm (an ECG) and your potassium and magnesium levels, and correct them if needed. Tell yo… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Buprenorphine or Zuclopenthixol need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (4)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: BUTRANS(R) transdermal system patch, buprenorphine transdermal system patch. Purdue Pharma L.P. (per FDA), Stamford, CT, 2016. DailyMed
- Product Information: BELBUCA(TM) buccal film, buprenorphine buccal film. Endo Pharmaceuticals Inc. (per FDA), Malvern, PA, 2016.
- Product Information: BUPRENEX(R) intravenous injection, intramuscular injection, buprenorphine HCl intravenous injection, intramuscular injection. Indivior Inc. (per DailyMed), Richmond, VA, 2016. DailyMed
Keep reading about Buprenorphine
Keep reading about Zuclopenthixol
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist